2012-05-30
Professor Carl-Henrik Heldin strengthens the Board of Kancera
Kancera announces that Professor Carl-Henrik Heldin has been elected to Kancera ́s Board at the company's annual general meeting May 28.
Read More
2012-05-23
Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia
Kancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research group at the Karolinska University Hospital conducted the studies.
Read More
2012-05-21
A new diagnostic tool increases the value of Kancera´s ROR technology
Kancera has, in collaboration with Professor Håkan Mellstedt's research group at the Karolinska Institute, developed antibodies that permit the development of a diagnostic tool to identify patient response to treatment using Kancera's ROR inhibitors.
Read More
2012-05-11
Data indicate broad utility of Kancera’s PFKFB3 inhibitors.
Kancera AB (publ), Sweden, has demonstrated effect with their PFKFB3 inhibitors in cells from three different types of solid tumors. In addition to the previously reported enhancement on effects off cisplatin's effect ion gastric cancer cells, the company has...
Read More
2012-04-23
Kancera presents at Boston seminar April 27th, 2012.
Kancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and Structure-Based Drug Design in Cancer Research".
Read More
2012-04-18
Kanceras ROR project has been selected for presentation at the ASCO annual meeting in Chicago.
Kancera announced today that American Society of Clinical Oncology has selected Kancera's ROR project for presentation at this year's major conference in Chicago on June 1-5, 2012.The scientific results will be presented by Professor Håkan Mellstedt in a paper...
Read More
2012-03-21
Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.
Kancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...
Read More
2012-02-10
Kancera’s ROR-inhibitor provides higher specificity than competing products
On February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation Dr. Olin described how Kancera, in collaboration with...
Read More
2012-02-03
Kancera file patents for ROR inhibitors against cancer
Kancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's ROR technology directed against both leukemia and solid tumors....
Read More
2012-02-02
Kanceras strategy is given attention when global expertise in cancer gathers in Washington DC
Today Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts in oncology from both the pharmaceutical industry and academia....
Read More